Kadono, Y., Kawaguchi, S., Nohara, T., Shigehara, K., Izumi, K., Kamijima, T., Seto, C., Takano, A., Yotsuyanagi, S., Nakagawa, R., Miyagi, T., Aoyama, S., Asahi, H., Fukuda, R., & Mizokami, A. (2021). Favorable Response of Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma with Only Small Lesions to not be Considered Measurable by RECIST. Urology Journal, 19(03), 202-208. https://doi.org/10.22037/uj.v18i.6652